Before a treatment: interactions between mushrooms, medications, and extracts

Yes, certain medicinal mushrooms can interact with medications. Reishi and cordyceps raise the most questions, particularly regarding anticoagulants, antidiabetics, and immunosuppressants. Before starting a regimen, the rule is simple: talk to your doctor or pharmacist, especially if you are on chronic treatment.

In brief:

• Mushrooms like reishi and cordyceps may increase the risk of bleeding or hypoglycemia when combined with anticoagulants or antidiabetics.
• Caution is necessary for patients on immunosuppressants, polytherapy, or suffering from liver or kidney disease, due to the metabolization of active compounds.
• The level of clinical evidence remains limited, but plausible mechanisms have been identified, especially for reishi and cordyceps, which require enhanced monitoring.
• All use of medicinal mushrooms should be subject to prior medical advice, especially before surgery or during chronic treatment.
• Warning symptoms include bleeding, unexpected hypoglycemia, dizziness, or a decrease in the effectiveness of immunosuppressive treatment.

Table of contents

• Mushroom-drug interactions: understanding the mechanisms at play
• Why these mushroom side effects matter for certain patients
• Reishi, cordyceps, chaga, lion’s mane, maitake, shiitake: what is the risk for each?
• Anticoagulants, immunosuppressants, antidiabetics: the medications to watch
• How to limit risks before taking a mushroom-based supplement
• Purecroft's position on formulation and medical vigilance
• What to remember about risks and precautions to take
• Which signs should alert you during a regimen?
• What do clinical cases and published studies show?
• Pregnancy, liver failure: who should avoid certain mushrooms?
• Between innovation and caution: my perspective on these supplements
• Purecroft extracts, an option to integrate with caution
• Sources

Mushroom-drug interactions: understanding the mechanisms at play

A drug interaction occurs when a substance alters the action of a medication, either by changing what the body does to the drug (pharmacokinetics) or by changing what the drug does to the body (pharmacodynamics). Medicinal mushrooms affect both registers simultaneously, which complicates risk assessment.

Several mechanisms appear frequently in the literature:

• Inhibition of platelet aggregation, driven in particular by reishi triterpenes, which can amplify the effect of anticoagulants.
• Immune modulation via beta-glucans, present in high proportions in shiitake and maitake, which comes into direct tension with immunosuppressants.
• An additive hypoglycemic effect, documented for cordyceps, which causes issues when combined with insulin or oral antidiabetics.
• A possible action on cytochrome CYP450 enzymes, which regulate the degradation of many common medications.

The level of evidence remains largely preclinical. The scientific review dedicated to interactions between medicinal mushrooms and established medications describes plausible molecular mechanisms and calls for further pharmacokinetic studies before drawing definitive clinical conclusions.

Why these mushroom side effects matter for certain patients

On paper, these mechanisms remain abstract. In practice, they translate into concrete consequences: prolonged bleeding after a cut, an unexpected drop in blood pressure, blood sugar levels that plummet for no apparent reason, or an immunosuppressive treatment losing its effectiveness at the wrong time.

Certain profiles deserve heightened vigilance:

• Patients on anticoagulants or antiplatelets (warfarin, apixaban, clopidogrel, aspirin).
• Transplant recipients, whose immunosuppressive treatment does not tolerate any interference.
• Diabetics on insulin or oral antidiabetics.
• People on polytherapy, where each additional molecule multiplies potential friction points.
• People with liver or kidney failure, whose ability to eliminate active substances is already reduced.

The most sensitive moments are surgical interventions, invasive exams, or any recent adjustment of dosage, periods during which close medical management significantly limits unpleasant surprises.

Reishi, cordyceps, chaga, lion’s mane, maitake, shiitake: what is the risk for each?

Each species has a distinct pharmacological profile, and the level of evidence varies significantly from one to another. Here is what we know, species by species.

1. Reishi. Its triterpenes have documented antiplatelet action, and case reports suggest a hypotensive effect and a possible slowing of the metabolism of certain medications via CYP450. The Merck Manual indicates an increased risk of bleeding in patients on anticoagulants or antiplatelets, as well as additive hypotension and hypoglycemia. This is the species for which the level of clinical evidence, through reported cases, is the strongest.

2. Cordyceps. Its hypoglycemic effect is relatively well-characterized, and a theoretical antiplatelet action is added to it. The Memorial Sloan Kettering Cancer Center explicitly recommends informing your healthcare team before taking it if you are on insulin or anticoagulant treatment. Caution is particularly necessary for diabetics.

3. Chaga. Antiplatelet activity has been observed in vitro, which justifies attention to the risk of bleeding, especially in combination with aspirin or other blood thinners. Data remain essentially preclinical.

4. Lion’s mane. Its neuroprotective benefits are relatively well-documented, but potential drug interactions with anticoagulants and antidiabetics remain signaled mainly by pharmacological summaries, without a large body of human studies. An analysis dedicated to lion's mane interactions highlights that the majority of reports come from in vitro or animal models, not clinical trials.

5. Maitake and shiitake. These two species are particularly rich in beta-glucans, molecules that stimulate the immune system. This is precisely what causes issues for patients on immunosuppressants, where the therapeutic goal is the opposite.

Key point: for most of these species, the risk remains theoretical, based on in vitro or animal data rather than large-scale clinical trials. This does not dispense with caution, but it invites distinguishing a risk documented by clinical cases (reishi, cordyceps) from a risk that is still primarily mechanistic (chaga, lion’s mane).

Anticoagulants, immunosuppressants, antidiabetics: the medications to watch

Certain classes of medications concentrate the majority of documented concerns. Knowing them allows one to target vigilance where it really counts.

• Anticoagulants and antiplatelets (warfarin, direct oral anticoagulants, clopidogrel, aspirin): the main risk is increased bleeding or an INR that becomes unstable, with unusual bruising or prolonged bleeding as warning signals.
• Immunosuppressants (used after a transplant or in certain autoimmune diseases): the beta-glucans in mushrooms stimulate immunity, which goes against the treatment's goal and can, in theory, reduce its effectiveness.
• Oral antidiabetics and insulin: the additive hypoglycemic effect of cordyceps, in particular, increases the risk of hypoglycemia, with sweats, tremors, or confusion to watch for.
• Antihypertensives: additive hypotension can translate into dizziness, unusual fatigue, or lightheadedness when standing up.
• Medications metabolized by CYP450 (certain statins, benzodiazepines, antidepressants): interference with these enzymes can change the plasma concentration of the medication, in either direction, with consequences difficult to predict without blood tests.

Pro tip: if you are taking an anticoagulant, ask your doctor to temporarily tighten the monitoring of your INR when starting a medicinal mushroom regimen. It is a simple, inexpensive exam, and it detects the problem before it becomes symptomatic.

Data on anticoagulants and hypoglycemics are based on case reports and clinical reviews, while interactions with CYP450 remain supported primarily by in vitro models.

How to limit risks before taking a mushroom-based supplement

Reducing the risk of interaction relies on a few simple reflexes to apply before even opening the bottle.

1. Inform your doctor or pharmacist, by bringing the product label with its list of ingredients and concentrations.
2. Ask specific questions: what interaction is expected with my treatment, which follow-up exams are relevant, what starting dosage is reasonable.
3. Start at a low dose and increase gradually to observe individual tolerance.
4. Stop taking them before surgery or invasive dental work, observing the delay indicated by your surgeon, due to the risk of bleeding.
5. Check the extraction method. An alcoholic extract concentrates more triterpenes, with an antiplatelet profile, while an aqueous extract concentrates more on beta-glucans, with an immunomodulatory profile. This difference directly guides the type of vigilance to adopt.